Tempest to Present at the Jefferies Global Healthcare Conference
01 June 2023 - 6:05AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-class1 therapeutics that
combine both targeted and immune-mediated mechanisms, today
announced that management will present at the Jefferies Global
Healthcare Conference on Wednesday, June 7, 2023 at 2:00 p.m. ET.
To access the live or archived recording of the
company presentation, please visit the investor section of the
Tempest website at https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company has a diverse portfolio
of novel programs ranging from early research to investigation in a
randomized global study in first-line cancer patients. The
company’s two novel clinical programs, TPST-1120 and TPST-1495,
target PPARα and EP2/EP4, respectively, and are advancing through
trials designed to study the agents as monotherapies and in
combination with approved agents. Tempest is also developing an
orally available inhibitor of TREX1, a target that controls
activation of the cGAS/STING pathway. Tempest is headquartered in
Brisbane, California. More information about Tempest can be found
on the company’s website at www.tempesttx.com.
Investor Contacts:
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
1 If approved by the FDA
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Apr 2024 to May 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From May 2023 to May 2024